Beijing Haibu Pharmaceutical Technology

Beijing Haibu Pharmaceutical Technology is a prominent Chinese Contract Research Organization (CRO) and drug development company specializing in small molecule pharmaceuticals. Established in 2005, the company offers a full suite of services including chemical synthesis, formulation development, clinical research, and regulatory affairs. Haibu Pharma is particularly recognized for its expertise in high-end generic drugs and the development of improved new drugs (Class 2 drugs in China). The company operates large-scale R&D centers and has successfully brought numerous products to the registration and market stages for its clients. It is listed on the National Equities Exchange and Quotations (NEEQ) in China.